The prognostic value of combined TyG and SIRI categories for cardiovascular disease and all-cause mortality among adults: Evidence from the NHANES 1999–2010
Aug 2026· American Heart Journal Plus: Cardiology Research and Practice· Vol 70, pp. 100857· 0 citations· 28 references
Medicine
TL;DR
Conurrently high TyG and SIRI identifies individuals at significantly increased mortality risk and this simple, threshold-based stratification may serve as a practical tool for cardiovascular risk assessment.
Abstract
Background The triglyceride-glucose (TyG) index and Systemic Inflammatory Response Index (SIRI) are markers of insulin resistance and inflammation, respectively, and are each independently associated with mortality. Their combined prognostic value is not well established. This study aimed to investigate the association between combined categories of TyG and SIRI and cardiovascular (CVD) and all-cause mortality. Methods We included 11,010 participants from the NHANES 1999–2010. All analyses accounted for the complex survey design. We employed Cox models, restricted cubic splines, and time-dependent ROC analyses. The incremental predictive value of the combined categories was assessed using the net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Results A TyG threshold of 8.64 (linear association) and an SIRI threshold of 0.63 (L-shaped association) were identified. Compared to the low-risk group (TyG ≤ 8.64 and SIRI≤0.63), participants with both TyG > 8.64 and SIRI>0.63 had a 68% higher risk of CVD mortality (HR = 1.68, 95% CI: 1.08–2.61, P = 0.021) and a 52% higher risk of all-cause mortality (HR = 1.52, 95% CI: 1.21–1.91, P < 0.0001). Adding the combined categories to a model of traditional risk factors significantly improved reclassification for CVD mortality (NRI = 0.15, P < 0.05). Subgroup and sensitivity analyses supported the robustness of the findings. Conclusions Concurrently high TyG and SIRI identifies individuals at significantly increased mortality risk. This simple, threshold-based stratification may serve as a practical tool for cardiovascular risk assessment.
It is suggested that TyG-derived inflammatory indices may hold clinical value in predicting mortality risk among patients with CKD, and in the first systematic comparison of multiple such indices, TyG-MLR emerged as the best-performing indicator, although its discriminative performance was moderate.
Rong-Wen Lin, Hui-Juan Zhao, Bo Wu· Science in progress· 0 citations
BACKGROUND AND AIMS
Insulin resistance and systemic inflammation are key drivers of atherosclerosis but are typically evaluated separately. This study aimed to determine whether integrating the triglyceride-glucose (TyG) index with inflammatory markers improves long-term risk stratification for major adverse cardiovasc...
Zhao Ma, P. Zhu, Jing-Jing Xu et al.· Coronary Artery Disease· 0 citations
Background Malnutrition and immune status significantly influence the prognosis of diabetic kidney disease (DKD). However, the correlations between two novel nutritional–immune indices—geriatric nutritional risk index (GNRI) and prognostic nutritional index (PNI)—and the risk of all‐cause mortality (ACM) and cardiovasc...
Yimei Li, Jimei Song, Li-Ying Liu et al.· International Journal of End...· 0 citations
Highlights • Elevated GLR is independently associated with higher all-cause and CVD mortality in a J-shaped manner.• GLR showed comparable or modestly better discrimination than individual inflammatory biomarkers.• The association persisted across sensitivity, competing-risk, and subgroup analyses after multiple-testin...
MASLD significantly increases the risk of cardiovascular events and all-cause mortality (ACM). The impact of the C-reactive protein-triglyceride-glucose index (CTI) and its derivatives on mortality in the MASLD population remains unclear. This study aimed to investigate their associations with mortality in the MA...
Guang-Jie Tu, Hang Zhai, Jun-Ming Xu et al.· BMC Cardiovascular Disorders· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.